A Phase 3 interventional study of Haemophilus influenzae type b- and meningococcal (vaccine) and Infanrix™ penta in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 12 sites in Spain. Open to participants aged 31 Months to 33 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-20.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 63rd largest by enrollment of the 80 interventional ones that give a count, is one of 14 that started in 2006, is one of 48 in phase 3, and was the 26th registered.
176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.
Browse Haemophilus Infections studies →None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →
Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 31 Months to 33 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 14 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is below the median of 458 across 163 interventional studies indexed under Haemophilus Infections.
Median enrollment 445 across the 80 interventional studies, 270 across the 2 observational. Of the 81 that completed or were terminated, 55 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This protocol posting deals with objectives \& outcome measures of the extension phase at Months 18, 30, 42, 54 and 66 post booster. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00352963). The objectives \& outcome measures of the Booster phase/study are presented in a separate protocol posting (NCT number =NCT00323050).
The purpose of this study is to evaluate the persistence of meningococcal serogroup C and Hib antibodies on a yearly basis for a period of 5.5 years after booster vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
This multicenter study is open. No vaccine will be administered during this persistence phase of the study. The subjects were randomized in the primary vaccination study 217744/097 (DTPa-HBV-IPV-097) and will not be further randomized in this study. The study has 3 groups with Meningitec™ primed group as control. The protocol was amended to allow for enrollment of subjects of the Meningitec™ primed control group who were boosted with Meningitec™ after the end of the booster study as per new local reccommendation in Spain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
Biological: Haemophilus influenzae type b- and meningococcal (vaccine) · Biological: Infanrix™ penta
Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
Biological: Haemophilus influenzae type b- and meningococcal (vaccine) · Biological: Infanrix™ hexa · Biological: Engerix-B · Biological: NeisVac-C™ · Biological: Infanrix™ IPV/HIB
Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
Biological: Infanrix™ hexa · Biological: Meningitec™
Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
Intramuscular injection into the thigh as a birth dose
Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
Intramuscular injection into the thigh as primary vaccination at 4 months of age
Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:8
The cut-off value for the rSBA-MenC titers was equal to or above 1:8. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:32
The cut-off value for the rSBA-MenC titers was equal to or above 1:32. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Equal to or Above Cut-off Value of 1:128
The cut-off value for the rSBA-MenC titers was equal to or above 1:128. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)
rSBA-MenC Titers
Titers are expressed as Geometric Mean Titers (GMTs). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
Time frame: 18, 30, 42, 54 and 66 months after booster dose (day 0)
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 0.15 µg/mL (Microgram Per Milliliter)
The cut-off value was an anti-PRP concentration equal to or above 0.15 µg/mL (microgram per milliliter).
Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Concentrations Equal to or Above Cut-off Value of 1.0 µg/mL (Microgram Per Milliliter)
The cut-off value was an anti-PRP concentration equal to or above 1.0 µg/mL (microgram per milliliter).
Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)
Anti-PRP Concentrations
Concentrations are expressed as Geometric Mean Concentrations (GMCs) in µg/mL (microgram per milliliter).
Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 0.3 µg/mL (Microgram Per Milliliter)
The cut-off value was an anti-PSC concentration equal to or above 0.3 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Concentrations Equal to or Above Cut-off Value of 2.0 µg/mL (Microgram Per Milliliter)
The cut-off value was an anti-PSC concentration equal to or above 2.0 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)
Anti-PSC Concentrations
Concentrations for anti-PSC antibody were expressed as GMCs.
Time frame: 18, 30, 42, 54 and 66 months after the booster dose (day 0)
Number of Subjects With Serious Adverse Events
Serious adverse events assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
Time frame: From last study contact of the booster study (NCT00323050) to Month 66 after booster dose (day 0)
The follow-up timepoints include all subjects who came back for that timepoint. Therefore the amount of subjects who completed the previous timepoint does not correspond with the amount of subjects starting the following time-point per se.
| Milestone | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Started | 58 | 123 | 3 |
| Completed | 58 | 123 | 3 |
| Not completed | 0 | 0 | 0 |
| Milestone | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Started | 54 | 119 | 57 |
| Completed | 54 | 119 | 57 |
| Not completed | 0 | 0 | 0 |
| Milestone | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Started | 51 | 113 | 56 |
| Completed | 51 | 113 | 56 |
| Not completed | 0 | 0 | 0 |
| Milestone | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Started | 50 | 108 | 56 |
| Completed | 50 | 108 | 56 |
| Not completed | 0 | 0 | 0 |
| Milestone | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Started | 48 | 104 | 53 |
| Completed | 48 | 104 | 53 |
| Not completed | 0 | 0 | 0 |
The cut-off value for the rSBA-MenC titers was equal to or above 1:8. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 45; 96; 0) | 44 | 93 | 0 |
| Month 30 (N= 48; 101; 45) | 39 | 96 | 31 |
| Month 42 (N= 50; 110; 52) | 39 | 106 | 33 |
| Month 54 (N= 49; 106; 51) | 38 | 103 | 33 |
| Month 66 (N= 46; 101; 46) | 38 | 95 | 28 |
The cut-off value for the rSBA-MenC titers was equal to or above 1:32. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 45; 96; 0) | 40 | 93 | 0 |
| Month 30 (N= 48; 101; 45) | 36 | 94 | 25 |
| Month 42 (N= 50; 110; 52) | 38 | 100 | 30 |
| Month 54 (N= 49; 106; 51) | 37 | 100 | 29 |
| Month 66 (N= 46; 101; 46) | 37 | 88 | 25 |
The cut-off value for the rSBA-MenC titers was equal to or above 1:128. 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 45; 96; 0) | 27 | 82 | 0 |
| Month 30 (N= 48; 101; 45) | 27 | 80 | 12 |
| Month 42 (N= 50; 110; 52) | 30 | 89 | 13 |
| Month 54 (N= 49; 106; 51) | 27 | 86 | 15 |
| Month 66 (N= 46; 101; 46) | 28 | 69 | 18 |
Titers are expressed as Geometric Mean Titers (GMTs). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
| titer | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 45; 96; 0) | 221.5 (137.2 to 357.7) | 801.1 (570.3 to 1125.3) | 0 (0 to 0) |
| Month 30 (N= 48; 101; 45) | 109.1 (61.9 to 192.3) | 441.7 (309.4 to 630.6) | 40.3 (21.9 to 74.1) |
| Month 42 (N= 50; 110; 52) | 98.9 (56.7 to 172.5) | 409.8 (297.7 to 564.2) | 36.1 (20.4 to 63.8) |
| Month 54 (N= 49; 106; 51) | 90.4 (52.8 to 154.8) | 344.6 (255.9 to 463.9) | 36.7 (21.1 to 64.0) |
| Month 66 (N= 46; 101; 46) | 121.5 (71.0 to 207.9) | 227.6 (160.2 to 323.3) | 42.7 (22.3 to 81.8) |
The cut-off value was an anti-PRP concentration equal to or above 0.15 µg/mL (microgram per milliliter).
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 56; 122; 3) | 56 | 121 | 3 |
| Month 30 (N= 53; 113; 53) | 53 | 112 | 53 |
| Month 42 (N= 50; 110; 51) | 50 | 109 | 51 |
| Month 54 (N= 49; 106; 52) | 49 | 105 | 52 |
| Month 66 (N= 47; 101; 47) | 47 | 101 | 46 |
The cut-off value was an anti-PRP concentration equal to or above 1.0 µg/mL (microgram per milliliter).
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 56; 122; 3) | 44 | 112 | 3 |
| Month 30 (N= 53; 113; 53) | 36 | 98 | 40 |
| Month 42 (N= 50; 110; 51) | 33 | 91 | 34 |
| Month 54 (N= 49; 106; 52) | 27 | 86 | 35 |
| Month 66 (N= 47; 101; 47) | 26 | 84 | 26 |
Concentrations are expressed as Geometric Mean Concentrations (GMCs) in µg/mL (microgram per milliliter).
| µg/mL (microgram per milliliter) | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 56; 122; 3) | 2.921 (2.150 to 3.968) | 5.450 (4.390 to 6.766) | 2.547 (0.390 to 16.651) |
| Month 30 (N= 53; 113; 53) | 1.914 (1.383 to 2.648) | 3.524 (2.813 to 4.415) | 2.224 (1.578 to 3.133) |
| Month 42 (N= 50; 110; 51) | 1.735 (1.243 to 2.423) | 2.986 (2.395 to 3.722) | 2.005 (1.365 to 2.946) |
| Month 54 (N= 49; 106; 52) | 1.552 (1.154 to 2.087) | 2.688 (2.149 to 3.361) | 1.799 (1.267 to 2.555) |
| Month 66 (N= 47; 101; 47) | 1.602 (1.107 to 2.320) | 2.625 (2.113 to 3.261) | 1.763 (1.170 to 2.657) |
The cut-off value was an anti-PSC concentration equal to or above 0.3 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 56; 122; 0) | 38 | 100 | 0 |
| Month 30 (N= 52; 108; 53) | 19 | 58 | 19 |
| Month 42 (N= 49; 107; 52) | 17 | 52 | 17 |
| Month 54 (N= 46; 105; 52) | 14 | 52 | 17 |
| Month 66 (45; 99; 45) | 12 | 34 | 11 |
The cut-off value was an anti-PSC concentration equal to or above 2.0 µg/mL (microgram per milliliter). 0 has been put as an arbitrary value for Month 18 in the Infanrix Hexa/Meningitec Group, as it was not addressed for reasons explained in the participant flow section.
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 56; 122; 0) | 1 | 31 | 0 |
| Month 30 (N= 52; 108; 53) | 1 | 18 | 3 |
| Month 42 (N= 49; 107; 52) | 0 | 14 | 2 |
| Month 54 (N= 46; 105; 52) | 1 | 10 | 1 |
| Month 66 (N= 45; 99; 45) | 0 | 8 | 0 |
Concentrations for anti-PSC antibody were expressed as GMCs.
| µg/mL (microgram per milliliter) | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Month 18 (N= 56; 122; 0) | 0.50 (0.39 to 0.64) | 1.01 (0.80 to 1.29) | 0 (0 to 0) |
| Month 30 (N= 52; 108; 53) | 0.26 (0.21 to 0.33) | 0.47 (0.37 to 0.61) | 0.30 (0.23 to 0.39) |
| Month 42 (N= 49; 107; 52) | 0.25 (0.20 to 0.31) | 0.40 (0.32 to 0.51) | 0.28 (0.21 to 0.37) |
| Month 54 (N= 46; 105; 52) | 0.24 (0.19 to 0.30) | 0.36 (0.29 to 0.45) | 0.26 (0.20 to 0.32) |
| Month 66 (N= 45; 99; 45) | 0.22 (0.18 to 0.27) | 0.29 (0.23 to 0.36) | 0.22 (0.18 to 0.28) |
Serious adverse events assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
| subjects | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events | 0 | 0 | 0 |
Collected over From the last contact of the booster study (NCT00323050) until Month 66 after the booster dose (day 0).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Menitorix/Pediarix Group | — | 0/58 (0%) | — |
| Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | — | 0/123 (0%) | — |
| Infanrix Hexa/Meningitec Group | — | 0/57 (0%) | — |
| Age, Continuous(Months) | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group | Total |
|---|---|---|---|---|
| Mean | 31.3 ± 0.54 | 31.4 ± 0.64 | 31.5 ± 0.87 | 31.4 ± 0.68 |
| Sex: Female, Male(Participants) | Menitorix/Pediarix Group | Infanrix Hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group | Infanrix Hexa/Meningitec Group | Total |
|---|---|---|---|---|
| Female | 27 | 55 | 27 | 109 |
| Male | 31 | 68 | 30 | 129 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2006, a primary completion of Jul 2006 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 4 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pediarix